Immune monitoring of infectious complications in transplant patients: An important step towards improved clinical management

Journal of Clinical Microbiology

Volumn 56, Issue 4, 2018, Pages

  Khannaa, Rajiv ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOMEGALOVIRUS ANTIGEN PP65; GAMMA INTERFERON; HLA ANTIGEN CLASS 1; PHYTOHEMAGGLUTININ; VALGANCICLOVIR; ANTIVIRUS AGENT;

ADOPTIVE TRANSFER; ANTIVIRAL THERAPY; BLOOD SAMPLING; CD8+ T LYMPHOCYTE; CELL THERAPY; CELLULAR IMMUNITY; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GRAFT RECIPIENT; HEART TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNE RECONSTITUTION; IMMUNE RESPONSE; IMMUNOREACTIVITY; IMMUNOREGULATION; IN VITRO STUDY; INCIDENCE; KIDNEY TRANSPLANTATION; LUNG TRANSPLANTATION; MALE; NONHUMAN; PRIORITY JOURNAL; RELAPSE; REVIEW; VIREMIA; VIRUS IMMUNITY; VIRUS LOAD; VIRUS REACTIVATION; VIRUS REPLICATION; CYTOMEGALOVIRUS; EVALUATION STUDY; IMMUNOLOGICAL MONITORING;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HEART TRANSPLANTATION; HUMANS; IMMUNITY, CELLULAR; MONITORING, IMMUNOLOGIC;

EID: 85043509654     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02009-17     Document Type: Review

References (37)

1. Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Snydman DR, Allen U, Humar A. 2010. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 89:779–795. https://doi.org/10.1097/TP.0b013e3181cee42f.
2. Gerna G, Lilleri D, Furione M, Castiglioni B, Meloni F, Rampino T, Agozzino M, Arbustini E. 2012. Human cytomegalovirus end-organ disease is associated with high or low systemic viral load in preemptively treated solid-organ transplant recipients. New Microbiol 35:279–287.
3. Gerna G, Lilleri D, Furione M, Baldanti F. 2011. Management of human cytomegalovirus infection in transplantation: validation of virologic cutoffs for preemptive therapy and immunological cut-offs for protection. New Microbiol 34:229–254.
4. Zamora MR, Davis RD, Leonard C. 2005. Management of cytomegalovirus infection in lung transplant recipients: evidence-based recommendations. Transplantation 80:157–163. https://doi.org/10.1097/01.TP.0000165430.65645.4F.
5. Humar A. 2006. Reactivation of viruses in solid organ transplant patients receiving cytomegalovirus prophylaxis. Transplantation 82(Suppl): S9–S14. https://doi.org/10.1097/01.tp.0000230432.39447.8b.
6. Fishman JA, Emery V, Freeman R, Pascual M, Rostaing L, Schlitt HJ, Sgarabotto D, Torre-Cisneros J, Uknis ME. 2007. Cytomegalovirus in transplantation-challenging the status quo. Clin Transplant 21:149–158. https://doi.org/10.1111/j.1399-0012.2006.00618.x.
7. Fernández-Ruiz M, Kumar D, Humar A. 2014. Clinical immune-monitoring strategies for predicting infection risk in solid organ transplantation. Clin Transl Immunology 3:e12. https://doi.org/10.1038/cti.2014.3.
8. Lisboa LF, Kumar D, Wilson LE, Humar A. 2012. Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia. Transplantation 93:195–200. https://doi.org/10.1097/TP.0b013e31823c1cd4.
9. Kotton CN, Huprikar S, Kumar D. 2017. Transplant infectious diseases: a review of the Scientific Registry of Transplant Recipients published data. Am J Transplant 17:1439–1446. https://doi.org/10.1111/ajt.14195.
10. Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Danziger-Isakov L, Humar A; Transplantation Society International CMV Consensus Group. 2013. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 96: 333–360. https://doi.org/10.1097/TP.0b013e31829df29d.
11. Kotton CN. 2013. CMV: prevention, diagnosis and therapy. Am J Transplant 13(Suppl 3):S24–S40. https://doi.org/10.1111/ajt.12006.
12. Crough T, Khanna R. 2009. Immunobiology of human cytomegalovirus: from bench to bedside. Clin Microbiol Rev 22:76–98, table of contents. https://doi.org/10.1128/CMR.00034-08.
13. Gandhi MK, Khanna R. 2004. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis 4:725–738. https://doi.org/10.1016/S1473-3099(04)01202-2.
14. Smith C, Khanna R. 2013. Immune regulation of human herpesviruses and its implications for human transplantation. Am J Transplantation 13(Suppl 3):9–23. https://doi.org/10.1111/ajt.12005.
15. Walker S, Fazou C, Crough T, Holdsworth R, Kiely P, Veale M, Bell S, Gailbraith A, McNeil K, Jones S, Khanna R. 2007. Ex vivo monitoring of human cytomegalovirus-specific CD8 T-cell responses using QuantiFERON-CMV. Transpl Infect Dis 9:165–170. https://doi.org/10.1111/j.1399-3062.2006.00199.x.
16. Elkington R, Walker S, Crough T, Menzies M, Tellam J, Bharadwaj M, Khanna R. 2003. Ex vivo profiling of CD8-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers. J Virol 77:5226 –5240. https://doi.org/10.1128/JVI.77.9.5226-5240.2003.
17. Chiereghin A, Potena L, Borgese L, Gibertoni D, Squarzoni D, Turello G, Petrisli E, Piccirilli G, Gabrielli L, Grigioni F, Lazzarotto T. 2018. Monitoring of cytomegalovirus (CMV)-specific cell-mediated immunity in heart transplant recipients: clinical utility of the QuantiFERON-CMV assay for management of posttransplant CMV infection. J Clin Microbiol 56: e01040-17. https://doi.org/10.1128/JCM.01040-17.
18. Lee H, Park KH, Ryu JH, Choi AR, Yu JH, Lim J, Han K, Kim SI, Yang CW, Chung BH, Oh EJ. 2017. Cytomegalovirus (CMV) immune monitoring with ELISPOT and QuantiFERON-CMV assay in seropositive kidney transplant recipients. PLoS One 12:e0189488. https://doi.org/10.1371/journal.pone.0189488.
19. Kwon JS, Kim T, Kim SM, Sung H, Shin S, Kim YH, Shin EC, Kim SH, Han DJ. 2017. Comparison of the commercial QuantiFERON-CMV and overlapping peptide-based ELISPOT assays for predicting CMV infection in kidney transplant recipients. Immune Netw 17:317–325. https://doi.org/10.4110/in.2017.17.5.317.
20. Kumar D, Mian M, Singer L, Humar A. 2017. An interventional study using cell-mediated immunity to personalize therapy for cytomegalovirus infection after transplantation. Am J Transplant 17:2468–2473. https://doi.org/10.1111/ajt.14347.
21. Han SH. 2017. Immunological prediction of cytomegalovirus (CMV) replication risk in solid organ transplantation recipients: approaches for regulating the targeted anti-CMV prevention strategies. Infect Che-mother 49:161–175. https://doi.org/10.3947/ic.2017.49.3.161.
22. Cantisán S, Páez-Vega A, Santos F, Rodríguez-Benot A, Aguado R, Rivero A, Montejo M, Torre-Cisneros J, Solana R; Spanish Network for Research in Infectious Diseases (REIPI). 2017. Impact of age and cytomegalovirus on CD8() T-cell compartment remodeling after solid organ transplantation: a one-year follow-up study. Exp Gerontol 95:98–106. https://doi.org/10.1016/j.exger.2017.04.011.
23. Tarasewicz A, Debska-Slizien A, Rutkowski B. 2016. Clinical utility of QuantiFERON-Cytomegalovirus test in management of kidney transplant recipients. Transplant Proc 48:1650–1653. https://doi.org/10.1016/j.transproceed.2016.01.046.
24. Cantisán S, Páez-Vega A, Pérez-Romero P, Montejo M, Cordero E, Gracia-Ahufinger I, Martín-Gandul C, Maruri N, Aguado R, Solana R, Torre-Cisneros J; Spanish Network for Research in Infectious Diseases (REIPI). 2016. Prevention strategies differentially modulate the impact of cytomegalovirus replication on CD8() T-cell differentiation in high-risk solid organ transplant patients. Antiviral Res 132:244 –251. https://doi.org/10.1016/j.antiviral.2016.06.012.
25. Sood S, Haifer C, Yu L, Pavlovic J, Gow PJ, Jones RM, Visvanathan K, Angus PW, Testro AG. 2015. Targeted individual prophylaxis offers superior risk stratification for cytomegalovirus reactivation after liver transplantation. Liver Transpl 21:1478–1485. https://doi.org/10.1002/lt.24216.
26. Schmidt T, Schub D, Wolf M, Dirks J, Ritter M, Leyking S, Singh M, Zawada AM, Blaes-Eise AB, Samuel U, Sester U, Sester M. 2014. Comparative analysis of assays for detection of cell-mediated immunity toward cytomegalovirus and M. tuberculosis in samples from deceased organ donors. Am J Transplant 14:2159–2167. https://doi.org/10.1111/ajt.12787.
27. Weseslindtner L, Kerschner H, Steinacher D, Kundi M, Jaksch P, Simon B, Hatos-Agyi L, Scheed A, Klepetko W, Puchhammer-Stockl E. 2013. Association of human cytomegalovirus DNAaemia and specific granzyme B responses in lung transplant recipients. Clin Exp Immunol 173:438–443. https://doi.org/10.1111/cei.12123.
28. Manuel O, Husain S, Kumar D, Zayas C, Mawhorter S, Levi ME, Kalpoe J, Lisboa L, Ely L, Kaul DR, Schwartz BS, Morris MI, Ison MG, Yen-Lieberman B, Sebastian A, Assi M, Humar A. 2013. Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clin Infect Dis 56:817–824. https://doi.org/10.1093/cid/cis993.
29. Abate D, Saldan A, Mengoli C, Fiscon M, Silvestre C, Fallico L, Peracchi M, Furian L, Cusinato R, Bonfante L, Rossi B, Marchini F, Sgarabotto D, Rigotti P, Palu G. 2013. Comparison of cytomegalovirus (CMV) enzyme-linked immunosorbent spot and CMV quantiferon gamma interferon-releasing assays in assessing risk of CMV infection in kidney transplant recipients. J Clin Microbiol 51:2501–2507. https://doi.org/10.1128/JCM.00563-13.
30. Giulieri S, Manuel O. 2011. QuantiFERON(R)-CMV assay for the assessment of cytomegalovirus cell-mediated immunity. Expert Rev Mol Diagn 11:17–25. https://doi.org/10.1586/erm.10.109.
31. Cantisán Bohórquez S, Navarro Ortega D. 2011. Immunological monitoring strategies for cytomegalovirus infection. Immune-based therapies. Enferm Infecc Microbiol Clin 29(Suppl 6):S28–S32. (In Spanish.) https://doi.org/10.1016/S0213-005X(11)70054-4.
32. Weclawiak H, Mengelle C, Ould Mohamed A, Izopet J, Rostaing L, Kamar N. 2010. Cytomegalovirus effects in solid organ transplantation and the role of antiviral prophylaxis. Nephrol Ther 6:505–512. (In French.) https://doi.org/10.1016/j.nephro.2010.06.003.
33. Lochmanova A, Lochman I, Tomaskova H, Marsalkova P, Raszka J, Mrazek J, Dedochova J, Martinek A, Brozmanova H, Grundmann M. 2010. Quantiferon-CMV test in prediction of cytomegalovirus infection after kidney transplantation. Transplant Proc 42:3574 –3577. https://doi.org/10.1016/j.transproceed.2010.07.101.
34. Kumar D, Chernenko S, Moussa G, Cobos I, Manuel O, Preiksaitis J, Venkataraman S, Humar A. 2009. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am J Transplant 9:1214–1222. https://doi.org/10.1111/j.1600-6143.2009.02618.x.
35. Westall GP, Mifsud NA, Kotsimbos T. 2008. Linking CMV serostatus to episodes of CMV reactivation following lung transplantation by measuring CMV-specific CD8 T-cell immunity. Am J Transplant 8:1749–1754. https://doi.org/10.1111/j.1600-6143.2008.02294.x.
36. Cantisán S, Lara R, Montejo M, Redel J, Rodríguez-Benot A, Gutiérrez-Aroca J, González-Padilla M, Bueno L, Rivero A, Solana R, Torre-Cisneros J. 2013. Pretransplant interferon-gamma secretion by CMV-specific CD8 T cells informs the risk of CMV replication after transplantation. Am J Transplant 13:738–745. https://doi.org/10.1111/ajt.12049.
37. Cantisán S, Rodelo-Haad C, Páez-Vega A, Nieto A, Vaquero JM, Poyato A, Montejo M, Fariñas MC, Rivero A, Solana R, Martín-Malo A, Torre-Cisneros J. 2015. Factors related to the development of CMV-specific CD8 T cell response in CMV-seropositive solid organ transplant candidates. Am J Transplant 15:715–722. https://doi.org/10.1111/ajt.13012.